PMID- 38398421
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20240227
IS  - 2077-0383 (Print)
IS  - 2077-0383 (Electronic)
IS  - 2077-0383 (Linking)
VI  - 13
IP  - 4
DP  - 2024 Feb 15
TI  - Diabetes Mellitus Should Be Considered While Analysing Sarcopenia-Related 
      Biomarkers.
LID - 10.3390/jcm13041107 [doi]
LID - 1107
AB  - Sarcopenia is a chronic, progressive skeletal muscle disease characterised by low 
      muscle strength and quantity or quality, leading to low physical performance. 
      Patients with type 2 diabetes mellitus (T2DM) are more at risk of sarcopenia than 
      euglycemic individuals. Because of several shared pathways between the two 
      diseases, sarcopenia is also a risk factor for developing T2DM in older patients. 
      Various biomarkers are under investigation as potentially valuable for sarcopenia 
      diagnosis and treatment monitoring. Biomarkers related to sarcopenia can be 
      divided into markers evaluating musculoskeletal status (biomarkers specific to 
      muscle mass, markers of the neuromuscular junction, or myokines) and markers 
      assuming causal factors (adipokines, hormones, and inflammatory markers). This 
      paper reviews the current knowledge about how diabetes and T2DM complications 
      affect potential sarcopenia biomarker concentrations. This review includes 
      markers recently proposed by the expert group of the European Society for the 
      Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal 
      Diseases (ESCEO) as those that may currently be useful in phase II and III 
      clinical trials of sarcopenia: myostatin (MSTN); follistatin (FST); irisin; 
      brain-derived neurotrophic factor (BDNF); procollagen type III N-terminal peptide 
      (PIIINP; P3NP); sarcopenia index (serum creatinine to serum cystatin C ratio); 
      adiponectin; leptin; insulin-like growth factor-1 (IGF-1); dehydroepiandrosterone 
      sulphate (DHEAS); C-reactive protein (CRP); interleukin-6 (IL-6), and tumor 
      necrosis factor alpha (TNF-alpha). A better understanding of factors influencing these 
      biomarkers' levels, including diabetes and diabetic complications, may lead to 
      designing future studies and implementing results in clinical practice.
FAU - Rentflejsz, Justyna
AU  - Rentflejsz J
AUID- ORCID: 0000-0002-2732-0982
AD  - Doctoral School, Medical University of Bialystok, 15-089 Bialystok, Poland.
AD  - Department of Geriatrics, Medical University of Bialystok, 15-471 Bialystok, 
      Poland.
FAU - Wojszel, Zyta Beata
AU  - Wojszel ZB
AUID- ORCID: 0000-0002-6472-5241
AD  - Department of Geriatrics, Medical University of Bialystok, 15-471 Bialystok, 
      Poland.
LA  - eng
GR  - B.SUB.23.108/Medical University of Bialystok/
PT  - Journal Article
PT  - Review
DEP - 20240215
PL  - Switzerland
TA  - J Clin Med
JT  - Journal of clinical medicine
JID - 101606588
PMC - PMC10889814
OTO - NOTNLM
OT  - adipokines
OT  - aging
OT  - biomarkers
OT  - hormones
OT  - inflammatory markers
OT  - myokines
OT  - older people
OT  - sarcopenia
OT  - type 2 diabetes mellitus
COIS- The authors declare no conflicts of interest.
EDAT- 2024/02/24 11:44
MHDA- 2024/02/24 11:45
PMCR- 2024/02/15
CRDT- 2024/02/24 01:13
PHST- 2023/12/11 00:00 [received]
PHST- 2024/02/02 00:00 [revised]
PHST- 2024/02/11 00:00 [accepted]
PHST- 2024/02/24 11:45 [medline]
PHST- 2024/02/24 11:44 [pubmed]
PHST- 2024/02/24 01:13 [entrez]
PHST- 2024/02/15 00:00 [pmc-release]
AID - jcm13041107 [pii]
AID - jcm-13-01107 [pii]
AID - 10.3390/jcm13041107 [doi]
PST - epublish
SO  - J Clin Med. 2024 Feb 15;13(4):1107. doi: 10.3390/jcm13041107.